APT-1011
Eosinophilic Esophagitis (EoE)
Phase 3Active
Key Facts
About Ellodi Pharmaceuticals
Ellodi Pharmaceuticals is a private, pre-revenue biotech company singularly focused on addressing the high unmet medical need in Eosinophilic Esophagitis (EoE). Its lead asset, APT-1011, is a Phase 3-stage oral therapy acquired from Adare Pharmaceuticals, positioning Ellodi as a late-stage contender in a market with no FDA-approved orally disintegrating treatment. The company is led by a seasoned team with deep GI and rare disease expertise, aiming to develop and commercialize transformative therapies for this underserved patient population.
View full company profileTherapeutic Areas
Other Eosinophilic Esophagitis (EoE) Drugs
| Drug | Company | Phase |
|---|---|---|
| AQ280 | Aqilion | Phase 1/Preclinical |
| ESO-101 | EsoCap | Phase 2 |
| '1104 | Revolo Biotherapeutics | Phase 2 |
| Solrikitug | Uniquity Bio | Phase 2 |
| Cendakimab | Bristol Myers Squibb | Phase 3 |
| Barzolvolimab | Celldex Therapeutics | Phase 2 |
| Vonoprazan | Phathom Pharmaceuticals | Phase 2 |